The heparins and cancer: review of clinical trials and biological properties (Q36021780)

11 August 2017

1 reference

title

The heparins and cancer: review of clinical trials and biological properties (English)

1 reference

11 August 2017

Roberto Castelli

1

1 reference

PubMed ID

15675186

11 August 2017

Fernando Porro

series ordinal

2

1 reference

PubMed ID

15675186

11 August 2017

Paolo Tarsia

series ordinal

3

1 reference

11 August 2017

1 May 2004

1 reference

11 August 2017

1 reference

11 August 2017

9

1 reference

11 August 2017

3

1 reference

11 August 2017

205-213

1 reference

The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.

11 August 2017

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Venous thromboembolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Laboratory diagnosis of the thrombophilic state in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

The thrombophilic state in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

The importance of blood cell-vessel wall interactions in tumour metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Thalidomide and thrombosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Central line thrombosis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Prevalence of pulmonary embolism at necropsy in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Cancer and thrombosis: mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Low-molecular-weight heparins in thrombosis and cancer: emerging links

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Extracellular matrix modulates expression of growth factors and growth-factor receptors in liver-colonizing colon-cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Evidence for effects of heparin on cell surfaces influencing experimental metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Control of angiogenesis with synthetic heparin substitutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Variations in the Size and Sulfation of Heparin Modulate the Effect of Heparin on the Binding of VEGF165 to Its Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X04VM566RA

10.1191/1358863X04VM566RA

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15675186